CN1788737A - 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 - Google Patents
一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 Download PDFInfo
- Publication number
- CN1788737A CN1788737A CNA2004100986604A CN200410098660A CN1788737A CN 1788737 A CN1788737 A CN 1788737A CN A2004100986604 A CNA2004100986604 A CN A2004100986604A CN 200410098660 A CN200410098660 A CN 200410098660A CN 1788737 A CN1788737 A CN 1788737A
- Authority
- CN
- China
- Prior art keywords
- preparation
- bacillus
- coagulated
- mycopowder
- living
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000193830 Bacillus <bacterium> Species 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims abstract description 46
- 206010009900 Colitis ulcerative Diseases 0.000 title claims description 49
- 201000006704 Ulcerative Colitis Diseases 0.000 title claims description 49
- 239000000203 mixture Substances 0.000 title claims description 30
- 238000009472 formulation Methods 0.000 title claims description 23
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims description 42
- 241000193749 Bacillus coagulans Species 0.000 claims description 34
- 229940054340 bacillus coagulans Drugs 0.000 claims description 31
- 238000000034 method Methods 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 13
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 13
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 11
- 230000003321 amplification Effects 0.000 claims description 11
- 238000001035 drying Methods 0.000 claims description 11
- 239000008103 glucose Substances 0.000 claims description 11
- 235000013336 milk Nutrition 0.000 claims description 11
- 239000008267 milk Substances 0.000 claims description 11
- 210000004080 milk Anatomy 0.000 claims description 11
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 11
- 239000008107 starch Substances 0.000 claims description 11
- 235000019698 starch Nutrition 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- 235000001727 glucose Nutrition 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 8
- 239000000594 mannitol Substances 0.000 claims description 8
- 235000010355 mannitol Nutrition 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 239000002552 dosage form Substances 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 238000000855 fermentation Methods 0.000 claims description 6
- 230000004151 fermentation Effects 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 238000009630 liquid culture Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 206010009887 colitis Diseases 0.000 abstract description 14
- 238000011156 evaluation Methods 0.000 abstract description 5
- 230000007774 longterm Effects 0.000 abstract description 2
- 238000012423 maintenance Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 25
- 238000000465 moulding Methods 0.000 description 20
- 230000000968 intestinal effect Effects 0.000 description 17
- 208000025865 Ulcer Diseases 0.000 description 15
- 231100000397 ulcer Toxicity 0.000 description 15
- 102000003896 Myeloperoxidases Human genes 0.000 description 11
- 108090000235 Myeloperoxidases Proteins 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 210000001072 colon Anatomy 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 7
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000001112 coagulating effect Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 5
- 238000000386 microscopy Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 210000000664 rectum Anatomy 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- 241000186016 Bifidobacterium bifidum Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 101710188689 Small, acid-soluble spore protein 1 Proteins 0.000 description 3
- 101710188693 Small, acid-soluble spore protein 2 Proteins 0.000 description 3
- 101710166422 Small, acid-soluble spore protein A Proteins 0.000 description 3
- 101710166404 Small, acid-soluble spore protein C Proteins 0.000 description 3
- 101710174019 Small, acid-soluble spore protein C1 Proteins 0.000 description 3
- 101710174017 Small, acid-soluble spore protein C2 Proteins 0.000 description 3
- 101710174574 Small, acid-soluble spore protein gamma-type Proteins 0.000 description 3
- 102100036407 Thioredoxin Human genes 0.000 description 3
- 210000000436 anus Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 210000003097 mucus Anatomy 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000036649 Dysbacteriosis Diseases 0.000 description 2
- 208000027244 Dysbiosis Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 206010057071 Rectal tenesmus Diseases 0.000 description 2
- 241000209149 Zea Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 201000009840 acute diarrhea Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 208000003455 anaphylaxis Diseases 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000007821 culture assay Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000007140 dysbiosis Effects 0.000 description 2
- 230000003628 erosive effect Effects 0.000 description 2
- 150000002304 glucoses Chemical class 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000003305 oral gavage Methods 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 description 2
- 229960001940 sulfasalazine Drugs 0.000 description 2
- 208000012271 tenesmus Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 102100024522 Bladder cancer-associated protein Human genes 0.000 description 1
- 101150110835 Blcap gene Proteins 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 206010022714 Intestinal ulcer Diseases 0.000 description 1
- 206010023799 Large intestinal ulcer Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 101100493740 Oryza sativa subsp. japonica BC10 gene Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 206010056626 Pseudopolyp Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 208000034972 Sudden Infant Death Diseases 0.000 description 1
- 206010042440 Sudden infant death syndrome Diseases 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009924 canning Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000000589 cicatrix Anatomy 0.000 description 1
- 238000002052 colonoscopy Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000001662 opsonic effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000001599 sigmoid colon Anatomy 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
组别 | 鼠数(只) | 体重(g) | 肠湿重(g/100g体重) | 溃疡或糜烂点 | MPO活性(U/g湿重) | |||
造型前 | 造型后 | 治疗后 | 点数 | 面积(cm2) | ||||
正常组造型组造型+生理盐水造型+凝结107造型+凝结106造型+SASP | 101010101010 | 88.0±9.2090.00±8.1686.00±8.4389.00±9.9493.00±9.4986.00±8.43 | 134.00±12.70127.00±8.23130.00±6.70127.00±9.50133.00±9.50131.00±8.80 | 292.00±14.00无255.00±16.50275.00±22.70△267.00±16.70264.00±13.50 | 0.50±0.041.26±0.080.61±0.07**0.48±0.05**△△0.50±0.05**△△0.54±0.05**△ | 04.20±0.923.50±0.971.80±1.238*△△1.60±1.07**△△2.20±0.79**△△ | 00.68±0.210.42±0.16**0.14±0.14**△△0.15±0.10**△△0.22±0.18**△ | 0.07±0.051.33±0.310.68±0.350.20±0.10**△△0.29±0.29*△△0.20±0.10**△△ |
组别 | 鼠数 | 肠湿重(g/100g体重) | 溃汤点数(点) | 溃疡面积(cm2) | MPO活性(u/g湿重) |
造型+生理盐水造型+TBC169造型+BC(日本株) | 101010 | 0.65±0.080.46±0.03**0.49±0.07** | 3.80±0.981.72±0.90**1.92±1.12** | 0.45±0.170.13±0.10**0.15±0.14** | 0.70±0.370.18±0.09**0.24±0.12** |
Claims (16)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100986604A CN100569243C (zh) | 2004-12-15 | 2004-12-15 | 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 |
US11/191,712 US20060127381A1 (en) | 2004-12-15 | 2005-07-28 | Live bacterial preparation of bacillus coagulans for the treatment of ulcerative colitis, method for producing the same and use thereof |
US11/763,094 US8092793B2 (en) | 2004-12-15 | 2007-06-14 | Treating inflammatory bowel disease with live bacteria |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100986604A CN100569243C (zh) | 2004-12-15 | 2004-12-15 | 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1788737A true CN1788737A (zh) | 2006-06-21 |
CN100569243C CN100569243C (zh) | 2009-12-16 |
Family
ID=36584179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100986604A Active CN100569243C (zh) | 2004-12-15 | 2004-12-15 | 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 |
Country Status (2)
Country | Link |
---|---|
US (1) | US20060127381A1 (zh) |
CN (1) | CN100569243C (zh) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110090230A (zh) * | 2018-01-30 | 2019-08-06 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
CN110607257A (zh) * | 2019-09-06 | 2019-12-24 | 吉林恩泽生物技术开发有限公司 | 一种用于预防溃疡性结肠炎的复合益生菌 |
CN111893072A (zh) * | 2020-08-13 | 2020-11-06 | 厦门惠盈动物科技有限公司 | 一种凝结芽孢杆菌菌粉的制备方法 |
CN111955719A (zh) * | 2020-07-06 | 2020-11-20 | 齐鲁工业大学 | 一种治疗炎症性肠病的特医食品及其制备方法 |
CN113198004A (zh) * | 2021-05-19 | 2021-08-03 | 天津市宝恒生物科技有限公司 | 一种修复肠粘膜的凝结芽孢杆菌制剂 |
CN114134080A (zh) * | 2021-12-06 | 2022-03-04 | 成都大学 | 一株凝结芽孢杆菌及其在结肠炎的治疗中的应用 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8092793B2 (en) * | 2004-12-15 | 2012-01-10 | Qingdao East Sea Pharmaceuticals, Ltd. | Treating inflammatory bowel disease with live bacteria |
CN101095698B (zh) * | 2006-06-26 | 2010-12-01 | 青岛东海药业有限公司 | 酪酸梭菌防治便臭毒素引起的相关症状和疾病的用途 |
CN101134052A (zh) * | 2006-11-17 | 2008-03-05 | 青岛东海药业有限公司 | 酪酸梭菌、凝结芽孢杆菌、双歧杆菌在制备防治口腔溃疡药物中的应用 |
US9814756B2 (en) | 2012-06-15 | 2017-11-14 | Temple University—Of the Commonwealth System of Higher Education | Use of isolated bacterial amyloids for treatment of inflammatory disorders or diseases of the epithelium |
CN109157657A (zh) * | 2018-09-29 | 2019-01-08 | 商丘美兰生物工程有限公司 | 鸡传染性法氏囊病活疫苗耐热冻干保护剂及其制备方法 |
CN112514849A (zh) * | 2020-12-16 | 2021-03-19 | 安徽中医药大学 | 一种硫酸葡聚糖钠诱导白色念珠菌预先定植的结肠炎模型的构建方法 |
CN114806930B (zh) * | 2022-03-31 | 2022-11-22 | 青岛东海药业有限公司 | 一种益生菌组合物及其应用 |
CN116121122B (zh) * | 2022-12-08 | 2023-10-03 | 玫斯江苏宠物食品科技有限公司 | 一种防治猫腹泻的益生菌复合制剂及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7767203B2 (en) * | 1998-08-07 | 2010-08-03 | Ganeden Biotech, Inc. | Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption |
WO2005019417A2 (en) * | 2003-08-14 | 2005-03-03 | The Bio Balance Corporation | Bacterial strains, compositions including same and probiotic use thereof |
-
2004
- 2004-12-15 CN CNB2004100986604A patent/CN100569243C/zh active Active
-
2005
- 2005-07-28 US US11/191,712 patent/US20060127381A1/en not_active Abandoned
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110090230A (zh) * | 2018-01-30 | 2019-08-06 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
CN110090230B (zh) * | 2018-01-30 | 2022-07-12 | 青岛东海药业有限公司 | 凝结芽孢杆菌在制备预防或治疗胆管癌制剂中的应用 |
CN110607257A (zh) * | 2019-09-06 | 2019-12-24 | 吉林恩泽生物技术开发有限公司 | 一种用于预防溃疡性结肠炎的复合益生菌 |
CN110607257B (zh) * | 2019-09-06 | 2023-09-08 | 吉林恩泽生物技术开发有限公司 | 一种用于预防溃疡性结肠炎的复合益生菌 |
CN111955719A (zh) * | 2020-07-06 | 2020-11-20 | 齐鲁工业大学 | 一种治疗炎症性肠病的特医食品及其制备方法 |
CN111893072A (zh) * | 2020-08-13 | 2020-11-06 | 厦门惠盈动物科技有限公司 | 一种凝结芽孢杆菌菌粉的制备方法 |
CN113198004A (zh) * | 2021-05-19 | 2021-08-03 | 天津市宝恒生物科技有限公司 | 一种修复肠粘膜的凝结芽孢杆菌制剂 |
CN113198004B (zh) * | 2021-05-19 | 2022-08-19 | 天津市宝恒生物科技有限公司 | 一种修复肠粘膜的凝结芽孢杆菌制剂 |
CN114134080A (zh) * | 2021-12-06 | 2022-03-04 | 成都大学 | 一株凝结芽孢杆菌及其在结肠炎的治疗中的应用 |
Also Published As
Publication number | Publication date |
---|---|
US20060127381A1 (en) | 2006-06-15 |
CN100569243C (zh) | 2009-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110122877B (zh) | 鼠李糖乳杆菌及其用途 | |
JP5112444B2 (ja) | カンジダ症及び尿路感染の予防及び/または治療のための発酵乳酸桿菌Ess−1、DSM17851及びそれの使用 | |
CN102586148B (zh) | 一种能够缓解铅毒性的植物乳杆菌及其用途 | |
CN102827796B (zh) | 一种具有排镉功能的植物乳杆菌及其用途 | |
CN101664421B (zh) | 一种防治畜禽腹泻的中药生物制剂及其制备方法和饲料 | |
CN100569243C (zh) | 一种治疗溃疡性结肠炎的凝结芽孢杆菌活菌制剂的制造方法和应用 | |
CN1119154C (zh) | 双歧三联活菌制剂及制备方法 | |
CN102174450B (zh) | 一种抗幽门螺杆菌感染的植物乳杆菌及其用途 | |
WO2022206300A1 (zh) | 可促进排便的组合物及其用途 | |
CN102091099A (zh) | 凝结芽孢杆菌制备治疗炎症性肠病药物中的应用 | |
CN101138573A (zh) | 酪酸梭菌、凝结芽孢杆菌制备治疗炎症性肠病药物中的应用 | |
CN114921389A (zh) | 一种具有女性肠私处护理和乳腺抗炎功效的益生菌组合物及其应用 | |
CN101336938B (zh) | 益生菌在制备治疗与预防手足口病组合物中的应用 | |
CN101134051A (zh) | 酪酸梭菌、凝结芽孢杆菌、双歧杆菌在制备治疗肠易激综合征、冷凉泻、喝酒泻药物中的应用 | |
CN106491657A (zh) | 一种加强调节肠道菌群功能的保健食品及其制备方法 | |
CN101134052A (zh) | 酪酸梭菌、凝结芽孢杆菌、双歧杆菌在制备防治口腔溃疡药物中的应用 | |
JPWO2005077390A1 (ja) | 血糖値低下剤、糖尿病治療・予防剤及びその製造方法 | |
CN105385640A (zh) | 格氏乳球菌及其应用 | |
CN108740294A (zh) | 一种复合菌种发酵胃肠活的制备方法 | |
CN101507759B (zh) | 预防和治疗脂溢性皮炎的中药组合物、制剂及其制备方法 | |
CN113967243B (zh) | 一种用于防治家禽腹泻的发酵中药制剂及其制备方法 | |
CN109172614A (zh) | 一种女性专用益生菌组合物及其应用 | |
CN1698691A (zh) | 一种治疗肺热(毒)咳嗽的药物及其制备方法 | |
CN1814221A (zh) | 一种治疗尿路感染的中药组合物及其制备方法 | |
CN115838649A (zh) | 一种用于肠道菌群调和的微生物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Yan Shucui Document name: Notice of conformity |
|
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING POURKANG MEDICINE HIGH SCIENCE AND TECHNOL Free format text: FORMER OWNER: BEIJING TIANSHIKANG MEDICINE SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. Effective date: 20091218 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20091218 Address after: Room 106, 5 building, Fucheng Road middle school, 131 Fuzi Road, Fucheng Road, Haidian District, Beijing, zip code: 100048 Co-patentee after: QINGDAO EASTSEA PHARMACEUTICAL Co.,Ltd. Patentee after: Beijing Puerkang Medicine Technology Co.,Ltd. Address before: Room 602, building 5, Fuguang 8, white pile, Fucheng Road, Haidian District, Beijing, zip code: 100037 Co-patentee before: QINGDAO EASTSEA PHARMACEUTICAL Co.,Ltd. Patentee before: TIANSHIKANG MEDICAL SCIENCE AN |